Dr. Luke Evnin joined the board of directors of Oxagen in May 2005. He is a general partner at MPM Capital which he joined in 1998 to launch MPM's first venture fund and established the San Francisco office for the firm in 1999. Previously Luke was at Accel Partners for over seven years including four as a General Partner. He was involved in biopharmaceutical, medical device and healthcare service companies for Accel's funds III, IV and V. He is currently a Director of BioValve, Enteromedics, Innovative Spinal Technologies, Intercell, Metabasis, Peptimmune and Restore Medical and was previously a Director at Idun Pharmaceuticals, Oscient Sonic Innovations, Epic Therapeutics, EPIX Medical, Signal Pharmaceuticals as well as several other private companies.

Luke earned his PhD in the Department of Biochemistry at the University of California-San Francisco, and he received his AB in Molecular Biology magna cum laude from Princeton University.